Russian medical researchers could launch a cancer vaccine within three years if there is sufficient funding and policy support, a senior official from the Russian Federal Medical and Biological Agency (FMBA) said on Thursday local time. The official, Vasily Lazarev, who is also a scientist, recently claimed: "If financial support is provided, I think that within two to three years, existing organizations will be able to transform cancer vaccines into actual clinical applications."
However, Lazarev did not elaborate on which type of cancer the vaccine that may soon be available targets, nor how it works.
A cancer vaccine is a biological agent designed to prevent or treat cancer. Unlike traditional vaccines, which work by activating the immune system to prevent infectious diseases, cancer vaccines are designed to activate the immune system to identify and destroy tumor cells.
Cancer vaccine research is currently in various stages, with some already approved for treatment of specific types of cancer, while others are still in clinical trials. Last year, the British government signed an agreement with German biotech company BioNTech to launch clinical trials to provide "personalized cancer treatments". Evaxion, a Danish technology and biotechnology company, announced in January that the company will develop customized cancer vaccines targeting new tumor antigens. Moderna and Merck are also developing experimental cancer vaccines.
These vaccines may use a variety of different mechanisms, including utilizing tumor-associated antigens to activate the immune system, or using viral vectors to deliver genes to produce antigens and activate an immune response.
However, the research and development of tumor neoantigens has previously faced legal restrictions, and it was only recently that Russian regulatory agencies relaxed the policy.
Lazarev noted that domestic private investors in Russia will also be attracted to the technology after regulatory pressure eases.
Furthermore, he did not raise any medical or technical challenges, but highlighted the legal constraints facing cancer vaccine development.
It should be noted that although cancer vaccines have great theoretical potential, they still face challenges in clinical application. Cancer is a very complex disease, and each type of cancer has its own unique characteristics and challenges, so developing effective cancer vaccines requires long-term research and clinical trials.
Lazarev said: "I don't know how quickly the relevant regulations will be formulated. It may take a year to resolve all regulatory issues. But we have the tools and the production equipment, and I think it will not be difficult to organize."
However, Lazarev emphasized that although it is feasible in terms of R&D and production, it will certainly not be cheap in terms of price, because only a few institutions specialized in cancer research, such as Moscow’s Blokhin Cancer Center or FMBA’s Brain and Neurotechnology Center, can meet the production requirements.
Just last month, Russian President Vladimir Putin also said that Russia is about to develop a cancer vaccine and that it will be put into use as a personal treatment method soon.
Putin said: "We are very close to developing cancer vaccines and a new generation of immunomodulatory drugs, and I hope that they will soon be effective in individual treatment."